Bern, Switzerland (ots/PRNewswire) – Polaroid Therapeuticsa Swiss-based biotech start-up, is developing advanced antimicrobial therapies to enhance patient outcomes worldwide. Today, the company is pleased to announce the achievement of significant pre-clinical milestones in developing its innovative medical device.
- Its proprietary innovative polymer technology reduces bacterial bioburden without triggering antimicrobial resistance, one of the top global public health threats
- The Advanced Wound Dressing (AWD) market is valued at 4.5 billion USD and is witnessing increasing demand and technological advancements
- The company is looking to expand development and commercial collaborations with industry leaders
Polaroid Therapeutics is creating a pioneering antimicrobial polymer technology. These safe and highly potent polymers disrupt bacterial cells in a unique mechanism of action. They have an immediate and long-lasting activity without causing antimicrobial resistance (AMR).
Today, the misuse and overuse of antimicrobials are the main drivers of AMR. When antibiotics and antimicrobial agents are used excessively or inappropriately, bacteria, viruses, fungi, and parasites can adapt to them, making these treatments less effective over time. According to the World Health Organization, AMR is one of the top global public health and development threats. It is estimated that bacterial AMR was directly responsible for 1.27 million global deaths in 2019 and contributed to 4.95 million deaths. (1)
OriginatingfromPolaroid,thebrandthatpioneeredthechemistrybehindanaloginstantphotography,PolaroidTherapeutics’missionistocreateamorehumanandmeaningfulworldthroughcutting-edgetechnologyandresearch.Thecompanyislookingtoexpandcollaborationswithindustryleadersinadvancedwoundcare,developsuperiorhealthcareproducts,andchampionapatient-centriccaresystemthatsetsnewstandardsinmedicaltreatmentandpatientexperience.Globally,1-2%ofthepopulationsuffersfromchronicwoundcomplicationseachyear.(2)Thisnumberofaffectedpatientswillincreaseasglobalpopulationscontinuetoage.Aswerecognizethegrowingneedforchronicwoundmanagement,thereisasignificantopportunitytoadvancehealthcarepractices.Byprioritizingeffectivetreatmentstrategiesforchronicwounds,wecanenhancepatientcareandoptimizehealthcareresources.Thisproactiveapproachisnotjustaboutimprovingpatientoutcomes;italsorepresentsasteptowardsamoreefficientandsustainablehealthcaresystemglobally.TheglobalAdvancedWoundDressing(AWD)marketwasvaluedat4.5billion(USD)in2022andisprojectedtoexpandatacompoundannualgrowthrate(CAGR)of4.5%from2023to2030,withantimicrobialproductsrepresentingaquarterofthetotalAWDmarket.Themarketiswitnessingincreasingdemanddrivenbytechnologicaladvancements,surgicalprocedures,andtherisingprevalenceofchronicwounds.ThispresentsanopportunityforPolaroidTherapeuticsanditspartnerstocapitalizeonsuperiorproductdevelopmentandanunwaveringfocusonimprovingpatientoutcomes.Asthemarketcontinuestoevolve,opportunitiesforinnovationandcollaborationareripe,positioningtheindustry–andthoughtleaderslikePolaroidTherapeutics–forsustainedgrowthandadvancement.RanFrenkel,CEOandCo-FounderofPolaroidTherapeuticssaid,”Weareoperatinginanincrediblycomplexspace.Globally,themedicalneedsremainunmet,meaningpatientsareatriskofseverelong-termcomplications.AtPolaroidTherapeutics,weaimtochangethis.Ourtechnologieswillbenefitbothpatientsandthewidercareecosystemand,inturn,repositionchronicwoundcareasnotsimplythemanagementof,buteffectivesolution.Peoplearesufferingandwebelievewecanalleviatethisonaglobalscale.”AboutPolaroidTherapeutics:PolaroidTherapeuticsisaSwiss-basedbiotechstart-upinthedevelopmentofinnovativeantimicrobialtechnology.IncubatedandspunoffbyPolaroid,thebrandthatpioneeredthechemistrybehindanalogueinstantphotography.PolaroidTherapeutics’missionistobringtolifethebestofPolaroid’svisionofcreatingamorehumanandmeaningfulworldthroughcutting-edgetechnologyandresearch.Foundedin2022,PolaroidTherapeuticsisdevelopingantimicrobialtherapiesbasedonproprietaryantibacterialtechnologytopreventandinhibitinfectionsinmultipleindications,suchasacuteandchronicwounds.Thisuniquetechnologyisabreakthroughsolutionthatdoesnotcreateantimicrobialresistance(AMR)-regardedasthemostprominentglobalthreattohealth.Contact:AbigailCarriganpolaroidTX@ragency.comPhoto-https://mma.prnewswire.com/media/2338334/Polaroid_Therapeutics__Core_Tech_Asset.jpgLogo-https://mma.prnewswire.com/media/2338335/Polaroid_Theraphuetics_Logo.jpg(1) World Health Organisation(2) Lindholm, C. and Searle, R. (2016) ‘Wound management for the 21st century: combining effectiveness and efficiency,’ International Wound Journal, 13(S2), pp. 5–15. https://doi.org/10.1111/iwj.12623.
3 BioMedGPS© 2022 Global Advanced Wound Dressing www.smarttrak.com
View original content:https://www.prnewswire.co.uk/news-releases/polaroid-therapeutics-completes-pre-clinical-milestones-in-the-development-of-superior-antimicrobial-technology-for-acute-and-chronic-wounds-302059016.html
Questions & Contact:
Contact:
07468 458598